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Abstract: According to the 2012 ESPGHAN criteria for 
diagnosis of celiac disease (CD), duodenal biopsy (DB) 
can be avoided in children with a clear malabsorption 
syndrome, anti-tissue transglutaminase IgA (tTG2) ≥ 10x 
the cut-off, anti-endomysium IgA (EMA) and HLA 
DQ2/DQ8 genes. The aim of this study is to report our 
experience and evaluate the accuracy of the actual 
guidelines.  
Patients and methods: This is a retrospective study 
conducted on all patients diagnosed CD from 2012 to 
2018 in our Center. For all patients enrolled were 
analyzed: data of family history, symptoms, serology, 
genetics, Marsh grade and follow-up. 
Results: A total of 481 children [mean age 6,4 yrs; F:M= 
1.8:1] were included in the study. The mean age of 
patients who were not subject to DB was lower (4.51 yrs) 
comparing with patients that received DB (6.48 yrs). Out 
of the 256 patients with anti-tTG2 ≥ 10 fold, 121 
underwent DB because of mild symptoms (84/121) or no 
symptoms (37/121). In all cases Marsh type 3 was found 
and HLA haplotypes was compatible with CD diagnosis.  
Conclusions: Our study confirms that the serology has a 
primary importance to diagnose CD, regardless of the 
symptoms. These data suggest that biopsy and HLA 
haplotypes search, in presence of anti-tTG2 IgA ≥ 10x 
the cut-off, are wasteful and unhelpful for the patients. 
 






 Celiac Disease (CD) is defined as a systemic 
immune-mediated disorder responsible for a permanent 
inflammatory enteropathy, caused by the ingestion of 
proteins contained in some cereals (gliadin in wheat, 
hordein in barley and secalin in rye) that are called 
prolamines, in people with specific human class II 
leukocyte antigen (HLA haplotype DQ2 and/or DQ8). 
CD is characterized by variable clinical 
manifestations that may include intestinal and 
extraintestinal signs and symptoms as well as by high 
titers of specific antibodies (Ab): autoantibodies against 
endomysium (EMA) and enzyme tissue transglutaminase 
type 2 (tTG2), as well as anti-food Ab against 
deamidated peptides of gliadin (DGP), and finally by a 
small intestine enteropathy (1). For many years CD has 
been diagnosed by demonstrating of a clear small bowel 
enteropathy related to gluten dependence. The first 
guidelines of ESPGHAN (European Society of 
Gastroenterology, Hepatology and Pediatric Nutrition), 
formulated in 1970, envisaged three biopsies for 
diagnostic confirmation: the first on a gluten-containing 
diet to demonstrate the damage of the duodenal mucosa, 
the second after exclusion diet to verify the clear 
improvement of the intestinal mucosa, and the last one 
during re-exposure (challenge) to observe the new 
deterioration of the mucosa (2). The diagnostic criteria 
were revised in 1990, establishing that the diagnosis was 
based on some mandatory criteria (characteristic 
histological alteration of the duodenal mucosa on gluten-
containing diet and unequivocal and complete clinical 
remission on a gluten-free diet) and also on accessory 
criteria as positive EMA since 1990 and anti-tTG2 since 
1997 at the time of diagnosis with their normalization on 
a gluten-free diet and compatibility of the genetic test 
with the presence of the HLA alleles (3). Those criteria 
can still be considered valid with some exceptions 
evaluated in the review of the criteria carried out in 2012 
by the ESPGHAN’s Working Group (1). Because of the 
current availability and reliability of the serological tests, 
the re-exposure to gluten (diagnostic challenge) is no 
longer considered necessary, except in some situations 
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Human tissue anti-transglutaminase antibodies type-2 
IgA and IgG. The IgA class anti-tTG2 Ab remains the 
first-use serological test. The anti-tTG2 class IgA Ab 
represent an excellent screening procedure characterized 
by high sensitivity (SE) (78-100%), specificity (SP) (90-
100%) and positive predictive value (PPV) (72%) and are 
considered the best serological screening marker for CD 
in individuals with normal serum IgA levels. (4,5). 
Despite being considered the most reliable test, even 
today it is very often prescribed, erroneously, in 
combination with other less sensitive serological markers 
such as anti IgG-class tTG2, with lower sensitivity, that 
should be limited to the few cases of serum IgA 
deficiency and, because of its higher costs, it should 
never replace the total IgA determination to exclude the 
immune deficiency syndrome of serum IgA. It has been 
well known that levels of anti-tTG2 IgA higher than 10 
times the cut-off value are associated to intestinal mucosa 
atrophy with a high probability (1). 
Antiendomysium IgA and IgG antibodies. It is a very 
reliable but operator-dependent test and therefore 
burdened, in inexperienced hands, with a certain amount 
of false negative and/or false positive results with low 
titer. The test for EMA is highly specific, close to 100% 
(SE 86-100%; SP 97-100%; PPV 83%) (6), however it 
should only be used as a confirmatory test for anti-tTG2 
IgA considering the high cost, use of animal substrate 
(monkey esophagus) and operator dependence (5). 
Antigliadin Deamidated antibodies IgA and IgG. IgA 
and IgG class anti deamidated gliadin Ab (DGP) have 
lower performance than anti-tTG2 and EMA and should 
be used exclusively in patients under three years of age 
(6). Anti-DGP Ab are incorrectly prescribed, quite 
frequently; they had been developed in 2006 as an 
alternative to IgA class anti-tTG2 for CD screening (7), 
although their performance was shown to be lower than 
the anti-tTG2, according to most literature data (4,8,9). 
Finally, the usefulness of IgG class anti-DGP should be 
limited to children under the age of three or in IgA 
deficient individuals. Determination of Anti-Gliadin Ab 
of 1st generation (AGA) is no longer recommended to 
identify individuals with CD, due to their low SE (42-
100%), SP (47-94%) and PPV (18-31%). However, the 
AGA test is still prescribed, not understandably, in a 
surprisingly high percentage of cases in different 
regional realities (12). 
Total IgA titration. One individual per 500 of the general 
population has a total IgA deficiency (values <6 mg/dl, 
dosed with a pediatric kit, when the laboratory indicates 
a result <25 mg/dl). In this case IgA class tests may result 
falsely negative and IgG class tests are very useful 
especially considering that total IgA deficiency is 
associated with a 10 times higher risk of having CD. 
HLA typing (Haplotype Search DQ2 / DQ8). This test has 
a high and almost absolute negative predictive value 
(close to 100%) but a low PPV and therefore its main role 
is to exclude (completely or almost completely) a CD 
diagnosis. It is useful in first-degree relatives, especially 
in children, to avoid redundant serological investigations 
by identifying subjects to be monitored periodically 
(every 2 years up to 6 years of life, every 4-5 years 
thereafter) due to the risk of developing the disease in 10-




III. THE ROLE OF INTESTINAL BIOPSY 
 
The accurate revision of CD diagnostic criteria 
achieved in the last 10 years has led to a certain loss of 
histology specificity due to image detection with slight 
damage of the duodenal mucosa, demonstrating that the 
enteropathy has partially lost its central role in the 
diagnostic approach of CD; at the same time, in the last 
10 years, the importance of serology and HLA typing has 
increased. Because of this reason, in 2012 a new 
diagnostic algorithm has been proposed mostly based on 
genetics and Ab. However, till now, it has been prudent 
to correlate always the histological features with clinical 
manifestations, serological and genetic tests. 
 
 
IV.THE “NEW” DIAGNOSTIC CRITERIA 
 
In 2012, the ESPGHAN’s group published new 
diagnostic criteria for CD with the aim of minimizing the 
inconvenience for patients, avoiding DB (1). The current 
problem is to be able to identify symptoms that could be 
assessed during the follow-up. It resulted that clinical 
suspects could be considered when referred to clear and 
unequivocal signs of malabsorption (celiac crisis, failure 
to thrive, iron anemia). It was also crucial to carefully 
consider the accuracy of laboratory tests used (10), better 
if carried out by the Reference Centers for diagnosis in 
order to contain costs, avoiding unnecessary waste. 
The correlation between elevated Ab titers and severe 
intestinal mucosal damage (11) was also highlighted in 
the revised protocol. The proposal by ESPGHAN is 
aimed at pediatric patients with a clinical picture of 
malabsorption and symptoms related to gluten intake, in 
presence of:  
- Serum anti-tTG2 IgA titers above 10 times 
upper limit of normal (10xULN) in a 
calibration-curve–based test;  
- Positive EMA-IgA in a second blood sample 
- Positive HLA-risk alleles. (HLA DQ2 and/or 
DQ8).  
Three phenotypes of patients had been defined in the 
current guidelines: patients with severe malabsorption 
(classical form), subjects with moderate-to-low risk of 
celiac disease (which include non-classical and 
subclinical forms) and celiac family members.  
Nonetheless it is common that screening diagnostic test 
for CD are overly prescribed also in very improbable 
cases, causing unjustified alarms and anxiety for the 
family that thus requires a "second opinion" from other 
specialists and/or diagnostic centers, hence increasing 
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costs for patients and for the National Health System 
(NHS) (12).  
The ESPGHAN’s working group is planning to publish 
some proposals to modify the protocol, which have also 
emerged from the examination of recent published series 
(10). A first proposal could concern the associated 
symptomatology: it appears quite evident that the 
greatest importance could be attributed to the Ab titers, 
regardless of the type of associated symptoms that do not 
necessarily have to be represented by malabsorption 
symptoms. Secondly: the genetic pattern would not seem 
to play a fundamental role in the proposal to avoid DB: 
in fact, if all the above criteria are met, the HLA is 
practically positive in 100% of the cases and therefore 
the test could be avoided thus realizing a significant 
reduction in spending of the NHS funds.  
The proposal to confirm the value of the IgA anti-tTG2 
Ab in a laboratory other than the first, remains with the 
EMA IgA test as confirmation. The doubt that remains is 
whether it is still necessary to maintain a double 
diagnosis protocol at this point, one for symptomatic 
patients and one for asymptomatic patients; it is probable 
that the latter is no longer indispensable. 
 
 
V.PREMISE AND OBJECTIVES 
 
The aim of this study is to evaluate the new 
diagnostic criteria, in particular the accuracy of serologic 
tests and their reliability to predict CD. A second 
objective is to understand the impact of HLA-typing, 
EMA-IgA and endoscopic findings in a CD diagnosis. 
 
VI.PATIENTS AND METHODS 
 
We collected data from a series of patients with 
diagnosis of CD performed from January 2012 to 
December 2018 in a tertiary Center for CD (Cava de’ 
Tirreni Campus of University Hospital of Salerno). 
A total of 642 new celiac diagnoses were 
performed, 481/642 (75%) were aged less than 18 years 
at the time of diagnosis with mean age of 6.94 years 
(+4.37) and an F:M ratio of 1.8: 1. 
A chart review regarding data about family 
history, symptoms at onset, serology tests, HLA 
genotype, Marsh stage of biopsy (if performed) and 
follow-up had been analyzed. 
Patients with anti-tTG2 IgA value exceeding 10 
times cut-off, according to ESPGHAN’s guidelines, 
received proposal of diagnosis avoiding DB, otherwise 
patients with values between 3-10 times underwent DB. 
Patients showing anti-tTG2 IgA between 1-3 times cut-
off were followed quarterly and, in case of persistent 
altered values, DB was performed. 
In the first year of application of the new 
ESPGHAN’s criteria (year 2012), DB was however 
planned for all patients regardless of clinical and 
laboratory findings to evaluate Positive Predictive Value 
(PPV) of the protocol.  
The collected data were inserted in an electronic 
sheet(Microsoft Excel®), checked and exported for 
subsequent statistical analysis. The results of the study 
were expressed in absolute and relative frequencies for 
qualitative variables and mean and standard deviation 
(SD) or median (Md) and interquartile range (IQR) for 
the quantitative variables. To compare quantitative 
variables between groups, Pearson correlation was used. 
Relevant results taken in consideration were those with 
P<0.05. All data analysis and graphic were done in 




In the first year of application of the new 
ESPGHAN’s criteria (year 2012), intestinal biopsy was 
performed in 59 of 61 patients with a PPV of 100%. All 
these patients had a histological grade of Marsh type 3. 
After 2012, over the following years the number of 




Fig.1 - Prevalence of CD diagnosis biopsy sparing during 
2012-2018 
(data from 2012 regard presumptive number of patients 
who could had avoid DB if applied ESPGHAN’s criteria) 
 
 
The flow-chart of final cohort is summarized in 
Fig. 2.Out of the overall 481 pediatric patients diagnosed 
for CD in our Center, a total of 256 patients presented 
anti-tTG2 IgA Ab titers >10xULN and 225 had Ab titers 
< 10xULN. A strong negative correlation was 
demonstrated between anti-tTG2 value and biopsy (-
0.229, p < 0.001). Overall, 28% (135/481) of the patients 
in our series didn’t undergo DB, while 346/481 
performed it and the histological degree was found to be 
“atrophic” (Marsh 3b or 3c) in 88% of them. 
 
Translational Medicine @ UniSa - ISSN 2239-9747 2019, 20(4): 13-18 
 
16 
































Median age of biopsy-sparing patients was 4.51 years [1-
17 yrs] while median of patients that underwent to biopsy 
was 6.48 years [1-17 yrs]. We found a significantly 
positive correlation between the age and biopsy (0.213 
with p value <0.001). On the contrary there was not 
significantly difference in terms of gender (-0.038 p 
value >0.05). With regards to the onset symptoms, in our 
cohort the 18,84% of patients was completely 
asymptomatic at diagnosis. 
 
 
Classical onset symptoms reported were irregular alvo 
(28.71%), irritability (5.38%), failure to thrive (39.70%), 
globous abdomen (14.69%) while non-classical 
symptoms were asthenia (13.36%), anemia (18.96%), 
constipation (12.13%), isolated vomiting (8.56%), loss 
of appetite (21.47%) and recurrent abdominal pain 
(25.39%). All patients biopsy sparing were symptomatic 
with negative correlation between symptoms and biopsy 
(-0.229 with p <0.05) Fig 3. 
 
  
Fig.3 - Correlation between age at diagnosis, Anti-tTG2  values, symptoms, gender and years of diagnosis with biopsy. Anti-tTgG2 and age at 
diagnosis were significantly correlated with biopsy
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The HLA risk was tested in 202/256 patients (79%) with 
antibody 10xULN: 163 carried the DQ2 (80.7%), 26 the 
DQ8 (12.9%), 12 both DQ2-DQ8 (5.9%) and 1 the DQ2-
DQ7 (0.5%).Fifty-three per cent (135/256) with antibody 
10xULN didn’t undergo DB and 121 however underwent 
DB, because of scarceness of symptoms (84/121) or 
discovered during familiar and territorial screening 
(37/121). It was largely reported I and II grade familiarity 
in our patients. All the 121 patients tested had a Marsh type 
3 histological grade. Seventy-height/121 patients had been 
tested for HLA risk that was present in all 78/78 cases. 
Fourteen patients were considered potential suspects at 
onset and were followed until diagnosis (2.9%). Mean age 
of these patients was 7.1 years with an F:M ratio 1.2:1. In 
this sub-group of patients the average level of anti-tTG2 
IgA was corresponding to 4xULN, with a range from 
1xULN to 6xULN. In all cases, HLA risk was present (13 






After the first year of application of the revised 
ESPGHAN’s criteria (year 2012) when the intestinal 
biopsy was performed in almost all patients (97%) with the 
declared purpose of testing their applicability, over the 
following years the number of patients progressively 
reached 79% of the total. Moreover, around 50% patients 
of our cohort benefited from this biopsy sparing approach, 
with reduced burden and risks of endoscopy and anesthesia. 
Since the publication of the 2012 ESPGHAN’s criteria, 
several authors investigated the accuracy of new criteria, 
both in children and adults (10, 13,14,15).  
The main strength of our study is the larger 
retrospective cohort from single tertiary center, with the 
same tTG2 tests being applied through a standardized 
system following all manufacturers’ directions, by using 
the same calibration curves on automatized machines with 
fixed settings, involving the same laboratory technicians. 
The sensitivity of anti-tTG2 IgA Ab was 
confirmed high and EMA improved the positive likelihood 
ratio and strongly correlated to diagnosis of CD. 
Median age of patients who did not perform DB 
was lower than those that performed it; this “age-effect” is 
likely due to the higher relevance of onset symptoms such 
as malabsorption in younger children.  
With regards to the onset symptoms, the classic 
onset symptoms were predominantly represented by 
irregular alvo and weight loss, whilst non-classical onset 
symptoms were mainly represented by anemia, inappetence 
and recurrent abdominal pain and it was not to be neglected 
the constipation present in 12% of the cases. This confirms 
that it is necessary to think about the diagnosis of CD even 
in the presence of non-usual onset symptoms. 
All the patients who underwent DB, despite Ab 
titre>10xULN, because of a mild or completely 
asymptomatic clinical picture, showed however mucosal 
atrophy.  
We also stress that the application of diagnostic 
criteria offers the possibility to avoid DB but this represents 
an option, not a mandatory rule, that must be discussed with 
the child’s parents, in the presence of a diagnosis that 
involves the adoption of a restrictive "quod vitam" diet. For 
this reason, they could request to the gastroenterologist to 
carry out in any case the histological examination of the 
duodenal mucosa in order to reach an absolute diagnostic 
certainty.  
Moreover, our data revealed that HLA-typing for 
DQ2/DQ8 does not improve accuracy of CD diagnosis 
without biopsies and can be omitted for this purpose, with 
100% of HLA-risk alleles in patients with anti-tTG2 IgA 
≥10xULN and positive EMA. 
The limitation is the retrospective nature of our 
study, as we considered only patients with diagnosis of CD 
and potential disease without other differential diagnosis, 
that could represent a bias in our cohort. 
In our cohort only 2.9% of potential celiacs were 
diagnosed. In this group the average level of anti-tTG2 IgA 
was about 4xULN, ranging from 1x to 6x. In no case did 
the Ab titer exceed 6x the limit with EMA IgA present in 
all cases and all were HLA positive. In our Center, over the 
last years, a new line of conduct has been established that 
foresees a vigilant waiting in cases of anti-tTG2 IgA < 
3xULN with accurate follow-up and this has certainly 
determined a lower incidence of diagnosis of potential CD 
avoiding to subject to DB the patients with very low Ab 
titers. This strategy makes it possible to select the group of 
potential CD that tends to maintain positive serology over 
the years and that, often after some time, develops the 





This study confirms that the ESPGHAN biopsy-
sparing approach allows a correct diagnosis of CD while 
saving costs for health care systems as well as discomfort 
for the patients. 
Nonetheless some adjustments are needed in analyzing our 
experience in the current study. 
An important proposal is to modify the current guidelines 
concerning clinical scenarios: it is quite clear that the 
greatest importance is to be attributed predominantly to the 
Ab titer > 10xULN, regardless of the type of associated 
symptoms that do not necessarily have to be represented by 
malabsorption symptoms or others “classical” symptoms. 
An additional point regards genetic pattern that does not 
seem to play a fundamental role in the proposal to avoid 
DB: in fact, if the aforementioned criteria are met, HLA is 
positive in 100% of the cases and therefore the test could 
be avoided, thus realizing an important reduction in 
spending for the health care systems. 
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